Dr. Michael Pace has more than 9 years of clinical research experience within the academic and CRO sectors, with an exclusive focus on global and strategic clinical trial feasibility within the last 4 years. A significant portion of his CRO experience has been dedicated to the feasibility of solid tumor and hematological malignancy trials, spanning from early phase dose escalation trials to larger phase II/III global programs. He provides extensive experience in integrating critical strategic and data elements into clinical trial strategies. Dr. Pace also brings a comprehensive understanding of the constantly evolving gamut of data platforms utilized to plan clinical studies. From historical trial data to real-world evidence and patient EMR data sources, he is dedicated to providing custom, data-driven strategies for complex and challenging clinical studies.

His therapeutic expertise spans many fields and indications, including solid tumor and hematological malignancies, neurology, psychiatry, rare disease, cardiovascular, renal/metabolic disorders, dermatology and medical device.

Dr. Pace earned his Bachelor of Science in Biology and Neuroscience from Indiana University and his PhD in Biomedical Sciences from the University of Florida.

Why Analgesia?

“With a background as a neuroscientist, I’ve always been fascinated by pain research and the multidisciplinary approach that it necessitates. The public health impact of this type work is huge, and I’m thrilled to be involved in facilitating these types of trials at a time in which our society is in desperate need of more options for those experiencing pain.”

This is what drives Michael:

“During my tenure as a scientific researcher in graduate school, I spent countless hours at the lab bench attempting to understand the underlying causes of some of the most crippling diseases that impact our societies. However, throughout this process, I always felt removed from the patients that benefit from these research efforts. I felt like I was on the sidelines as many members of my family passed away from the very diseases I was researching, such as my grandfather to hepatocellular carcinoma or grandmother to Alzheimer’s disease. Shifting my career to be directly involved in the planning of clinical trials has been immensely rewarding, both personally and professionally. Bearing witness to the array of clinical research efforts put forth not only by my colleagues, but also by our clients gives me hope that fewer individuals will have to feel on the sidelines as their friends and family members continue to be affected by the diseases that our work seeks to cure.”